In the phase 3 SELECT-PsA 1 & SELECT-PsA 2 trials, results showed that a new generation JAK inhibitor offered an efficacy advantage without sacrificing safety, and showed sustained lasting response at week 56 in adults with active psoriatic arthritis. In this video, Dr. Rohekar will review the safety and efficacy data from these trials, as presented at the 2021 EULAR Virtual Conference. She will also examine long term data that show both doses were comparable across multiple endpoints.

The PARADIGM-HF trial previously established ARNI as one of the CCS/CHFS guideline-recommended pillars of treatment in heart failure with reduced ejection fraction. Building on these results, the PARADISE-MI trial asked the question as to whether patients with increased risk for developing heart failure should be started on an ARNI. In this program, Dr. Mielniczuk reviews the results of the trial, specific subgroup populations and whether treatment with an ARNI shows an advantage over time.

In the ASCLEPIOS trials, results showed that a targeted therapy offered a significant efficacy advantage without sacrificing safety, relative to an immunomodulatory therapy in treatment-naïve RMS patients.

In this video, Dr. Baharnoori will review a new analysis of the safety and efficacy data from these trials, as presented at the AAN Virtual Conference 2021. She will also examine new findings that show early use of a high-efficacy therapy can reduce the occurrence of overt relapses while slowing progression independent of relapse activity (PIRA) in a broad patient population.

The core analysis of the EXPAND study showed that an active therapy was associated with significant reductions in MRI lesion activity and slowed brain volume loss in persons with SPMS. In this program, Dr. Arnold focuses on 5-year EXPAND extension results which provide evidence that continuous treatment with this targeted agent vs switching from placebo shows persistent differences in sustained efficacy on MRI parameters over the long term. These results highlight the importance of early treatment initiation in persons with SPMS.

Vascular endothelial growth factor (VEGF) inhibitors are a standard of care for diabetic macular edema (DME). This program discusses the results of the Protocol-T Extension Study and provides evidence that anti-VEGF therapy reduces the risk of visual loss from DME for at least five years. Also discussed is whether tighter maintenance therapy over the extension period may have resulted in better clinical outcomes.

Each of four therapies now regarded as the pillars of treatment for HFrEF have demonstrated a survival benefit, and the 2021 CCS guidelines for HFrEF define prompt, concomitant treatment with all four therapies as a first-line standard, irrespective of age or concomitant T2DM. Dr. Connelly refers to these latest guidelines and published literature to highlight that an ARNI reverses, and not just slows, the underlying pathology of HFrEF. The goal is prompt initiation of this therapy, like the other pillars, in HFrEF patients with or without T2DM.

This video showcases Dr. Thanassoulis and Dr. Lavoie discussing their unique perspectives on the urgency of treating Atherosclerotic Cardiovascular Disease (ASCVD) patients not achieving low-density lipoprotein cholesterol (LDL-C) targets by overcoming root causes of treatment inertia and nonadherence. A focus will be placed on initiating and sustaining behavioural changes in patients through education, motivational communication as well as implementing a benefit approach.
Moreover, in this engaging forum, experts will discuss how emerging add-on therapies can support and improve the lipid management landscape and achieve a durable response.

Until recently, children suffering from spinal muscular atrophy (SMA) have had little treatment options. Not only is the landscape changing, but the therapies are extremely promising regarding milestone development. This program features key takeaways from the phase 3 SPR1NT trial presented at the Muscular Dystrophy Association (MDA) Virtual Conference. Dr. MacKenzie will review the safety and efficacy of SMN1 gene therapy in SMA and provide further evidence that, the earlier the disease is treated, the better the outcome for the patient.

This program features key information drawn from secondary analyses of the EXPAND trial and provides further evidence that an active therapy in SPMS can preserve and, in some cases, improve cognitive function. Treatments that manage both physical disability and cognitive decline is key to optimizing treatment for persons with MS.

In patients with atrial fibrillation (AF), the standard of care has been treatment with a direct oral anticoagulant (DOAC). The Canadian Cardiovascular Society (CCS) guidelines were recently revised to focus on treatment adherence and persistence. This program will examine how these updates, focusing on an integrated care model, can improve clinical outcomes.

Dr. Dorian will provide further insight on the pragmatic approach to implementing and optimizing a patient-centered treatment, as well as the importance of long-term adherence and persistence to treatment.